SCHEMBL3278560

SCHEMBL3278560

O=C1CCCN1c1cccc(NCc2ccccc2)c1

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GAA P10253 1/20 0.57
NPC1 O15118 4/20 0.57
RAB9A P51151 4/20 0.57
TSHR P16473 2/20 0.57
MEN1 O00255 2/20 0.57
KMT2A Q03164 2/20 0.57
SMN1; SMN2 Q16637 1/20 0.57
L3MBTL1 Q9Y468 1/20 0.57
HPGD P15428 2/20 0.53
ALDH1A1 P00352 2/20 0.53
CYP1A2 P05177 1/20 0.53
CYP3A4 P08684 1/20 0.53
CYP2D6 P10635 1/20 0.53
CYP2C9 P11712 1/20 0.53
CYP2C19 P33261 1/20 0.53
PARP1 P09874 3/20 0.51
LMNA P02545 2/20 0.49
CDK2 P24941 1/20 0.46
USP2 O75604 1/20 0.46
CACNA2D1 P54289 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3230248 0.89 LMNA (0.57) GAANPC1RAB9ATSHRMEN1
SCHEMBL5217472 0.83 CTSD (0.58) NPC1RAB9ATSHRMEN1KMT2A
SCHEMBL1965542 0.80 LMNA (0.49) GAANPC1RAB9ATSHRMEN1
SCHEMBL1963799 0.79 HDAC4 (0.43) CYP1A2CYP3A4CYP2D6CYP2C9CYP2C19
SCHEMBL5224792 0.79 CTSD (0.56) NPC1RAB9ATSHRMEN1KMT2A
SCHEMBL3278554 0.78 NPC1 (0.79) GAANPC1RAB9ATSHRMEN1
SCHEMBL22797021 0.77 GAA (0.70) GAANPC1RAB9ATSHRMEN1
SCHEMBL632583 0.77 GAA (0.50) GAANPC1RAB9ATSHRMEN1
SCHEMBL8215904 0.77 FNTA (0.53) GAANPC1RAB9ATSHRMEN1
SCHEMBL15834294 0.77 HPGD (0.57) GAANPC1RAB9ATSHRMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2334637-B1 NOVEL POTASSIUM CHANNEL BLOCKERS JAPAN TOBACCO INC (JP) 2017-01-04 EP claimed
US-8372840-B2 Potassium channel blockers XENTION LIMITED (GB) 2013-02-12 US disclosed
US-20100087438-A1 New Potassium Channel Blockers XENTION LIMITED (GB) 2010-04-08 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100087438-A1 New Potassium Channel Blockers KCNJ2, KCNB1, KCNJ11 GAA 3871/4885NPC1 511/4885RAB9A 1126/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.